Recent reports have shown gefitinib, epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) induced marked improvement in ECOG performance status (PS) as first-line therapy in EGFR mutationpositive patients with extremely poor PS. EGFR mutations frequently occur in east-Asian, female, nonsmoking, adenocarcinoma patients, however they are occasionally detected in patients with nonadenocarcinomas or with a heavy smoking history. We describe a case in which EGFR mutation was detected in a male, current smoker, squamous cell carcinoma (SCC) patient with PS 4, who showed a marked response to the first-line gefitinib therapy. EGFR mutational analysis is recommended even for SCC patients especially in east-Asian populations.
Introduction
There have been important advances within the last decade in the medical treatment of advanced/metastatic NSCLC. Systemic chemotherapy, such as platinum-based doublet therapy has been shown to prolong overall survival when administered as a standard treatment (1) . More recently, the efficacy of EGFR-TKIs in the treatment of NSCLC has been proven, especially in EGFR mutationpositive patients (2) . Inoue et al. reported that gefitinib, EGFR-TKI induced a great improvement in ECOG performance status (PS) as the first-line therapy in EGFR mutationpositive patients with extremely poor PS, especially those who had previously been solely treated with best supportive care (3). Although EGFR mutations occur frequently in female, non-smoking, east-Asian patients with adenocarcinoma, they are occasionally detected in patients with nonadenocarcinomas or with a heavy smoking history. We herein report a squamous cell lung cancer (SCC) patient with extremely poor PS who harbored EGFR mutation and showed remarkable response to the first-line gefitinib therapy.
Case Report
A 56-year-old man, who was a heavy smoker (2 packs/ day for 35 years), presented with dyspnea and numbness in the left leg, and was diagnosed with poorly differentiated SCC (Fig. 1) . A chest computed tomography (CT) showed a large tumor in the upper lobe of the left lung. Positron emission tomography (PET) revealed multiple bone metastases, including the left pelvic bone, which was thought to be pressing on his sciatic nerve and inducing numbness in the left leg. He was referred to our hospital for palliative radiation therapy on the left pelvic bone. On admission, he was suffering from severe respiratory failure. A chest X-ray revealed that the left lung was totally atelectatic (Fig. 2a) , and a chest CT revealed a complete occlusion of the left main bronchus (Fig. 3a) . As he was in PS 4, he was not a candi- date for cytotoxic chemotherapy. After starting palliative radiation therapy, EGFR mutation (an in-frame deletional mutation in exon 19) was detected in a specimen of his lung tumor obtained by bronchoscopic biopsy. Given his condition we decided to administer gefitinib. Ten days later, a chest X-ray revealed that the completely occluded left main bronchus had re-opened and that the left lung atelectasis was considerably improved (Fig. 2b, 3b) . His respiratory condition and the numbness in his left leg had also improved. His PS improved from 4 to 2. However, two months after the initiation of gefitinib therapy, the tumor began to enlarge. We discontinued the gefitinib therapy to introduce second-line chemotherapy (docetaxel+gefitinib), which induced infusion reaction. After we discontinued second-line chemotherapy, tumor growth induced empyema and his general condition gradually deteriorated. He died five months after the initiation of gefitinib.
Discussion
Lung cancer is the leading cause of cancer death worldwide, with NSCLC accounting for approximately 85% of newly diagnosed cases. The current treatment guidelines have established platinum-based two-drug combination chemotherapy as the standard of care for patients with advanced NSCLC (4). More recently, the efficacy of EGFR-TKIs has been demonstrated for patients with NSCLC harboring EGFR mutation (2) . EGFR mutations occur frequently in female, non-smoking, east-Asian patients with adenocarcinoma (5) . Several recent papers have suggested that tumor molecular profiling may supersede these clinical selection factors for EGFR-TKI treatment in patients with NSCLC. Toyooka et al. reported that EGFR mutation was independently associated with a favorable prognosis in gefitinibtreated patients regardless of gender or smoking history (6) . In the present case, EGFR mutation was detected in a male, currently smoking, SCC patient, indicating that EGFR mutational analysis is more important than clinical characteristics and histology.
In the present case, SCC histology was determined with a small specimen obtained by a bronchoscopic biopsy. Travis et al. mentioned the limitation of diagnosis with a small biopsy sample, which occasionally leads to a controversial diagnosis in NSCLC (7). This limitation is due in part to histological heterogeneity, containing both adenocarcinoma and SCC components. Therefore, practical EGFR mutational analysis should be performed, especially when the diagnosis is based only on a small biopsy sample. To our knowledge, few studies have documented how effective EGFR-TKIs are in SCC patients harboring EGFR mutations (8) . However, recently Shukuya et al. reported that gefitinib is less effective in non-adenocarcinoma NSCLC harboring EGFR mutations than adenocarcinoma harboring EGFR mutations (9) . In the present case, progression-free survival was only two months. We speculate that this relatively short duration of response to gefitinib is due to the inherent EGFR mutant heterogeneity in the tumor. Sakurada et al. reported tissue heterogeneity of EGFR mutation in lung cancer (10) . We assume that the EGFR mutant component in the tumor showed some response, whereas the EGFR wild-type component remained resistant to gefitinib.
Considering the diagnostic limitations based on small bi- a b opsy samples, EGFR mutational analysis is strongly recommended even for SCC patients, especially in east-Asian populations, which have a high incidence of EGFR mutations. As little data has been gathered regarding the efficacy of EGFR-TKIs for SCC patients with EGFR mutations, further investigations are warranted.
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